title: The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis.
abstract: BACKGROUND
  The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia.
  
  
  METHODS
  Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1.
  
  
  RESULTS
  DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2).
  
  
  CONCLUSIONS
  Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.
authors.affiliation: Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Kishimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ujike
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Motohashi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Yuko
authors.initials: Y
authors.lastname: Okahisa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kotaka
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Harano
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Tokutaro
authors.initials: T
authors.lastname: Komiyama
authors.forename: Toru
authors.initials: T
authors.lastname: Hori
authors.forename: Yoshimoto
authors.initials: Y
authors.lastname: Sekine
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
authors.forename: Ichiro
authors.initials: I
authors.lastname: Sora
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Kuroda
mesh_terms: D000328:Adult; D002352:Carrier Proteins / Q000235:genetics*; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011605:Psychoses, Substance-Induced / Q000235:genetics*; D018709:Statistics, Nonparametric
chemical_list: D002352:Carrier Proteins; C432416:DTNBP1 protein, human; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D008694:Methamphetamine